| Literature DB >> 30834181 |
Lissethe Palomo-Ligas1, Filiberto Gutiérrez-Gutiérrez2, Verónica Yadira Ochoa-Maganda1, Rafael Cortés-Zárate3, Claudia Lisette Charles-Niño3, Araceli Castillo-Romero3.
Abstract
BACKGROUND: The protozoan Giardia lamblia is the causal agent of giardiasis, one of the main diarrheal infections worldwide. Drug resistance to common antigiardial agents and incidence of treatment failures have increased in recent years. Therefore, the search for new molecular targets for drugs against Giardia infection is essential. In protozoa, ionic channels have roles in their life cycle, growth, and stress response. Thus, they are promising targets for drug design. The strategy of ligand-protein docking has demonstrated a great potential in the discovery of new targets and structure-based drug design studies.Entities:
Keywords: Docking; Giardia lamblia; Molecular modeling; Potassium channel; Potential target
Year: 2019 PMID: 30834181 PMCID: PMC6397635 DOI: 10.7717/peerj.6430
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Sequences producing significant alignments with GiK by BLAST.
| Accession number | Organism | Type of channel | Score | Identities | Positives | |
|---|---|---|---|---|---|---|
| Kv | 32 | 0.33 | 15/49 (31%) | 29/49 (59%) | ||
| Kv | 32 | 0.51 | 15/43 (35%) | 25/43 (58%) | ||
| Kv | 33 | 0.20 | 16/39 (41%) | 25/39 (64%) | ||
| Kv | 28.9 | 8.6 | 18/66 (27%) | 36/66 (55%) | ||
| Multispecies Kv | 28.9 | 9.8 | 18/66 (27%) | 36/66 (55%) | ||
| Kv1.3 | 34.7 | 0.27 | 20/58 (34%) | 32/58 (55%) | ||
| Ion channel | 33 | 0.18 | 10/20 (50%) | 18/20 (90%) | ||
| Kv | 35 | 0.24 | 16/43 (37%) | 25/43 (58%) | ||
| Kv1.3 | 35.0 | 0.17 | 20/58 (34%) | 32/58 (55%) | ||
| Kv | 32.7 | 2.4 | 22/80 (28%) | 40/80 (50%) | ||
| Kv1.3 | 33.1 | 0.56 | 18/45 (40%) | 26/45 (58%) | ||
| Kv | 36 | 0.012 | 14/41 (34%) | 27/41 (66%) | ||
| Kv1.3 | 35.0 | 0.18 | 20/58 (34%) | 32/58 (55%) | ||
| Kv1.3 | 33.5 | 0.47 | 14/38 (37%) | 24/38 (63%) | ||
| Kv | 44 | 5e-04 | 33/105 (31%) | 53/105 (50%) | ||
| Kv | 36.6 | 0.032 | 17/67 (25%) | 34/67 (51%) | ||
| Kv | 29 | 5.3 | 18/66 (27%) | 36/66 (55%) | ||
| Kir | 32.0 | 1.9 | 18/67 (27%) | 34/67 (51%) | ||
| Kv | 30 | 0.54 | 9/34 (26%) | 24/34 (71%) | ||
| Kv | 31.6 | 1.9 | 12/49 (24%) | 27/49 (55%) | ||
| Kv | 31.6 | 1.3 | 27/91 (30%) | 46/91 (51%) |
Physicochemical characterization of GiK by Protparam.
| Number of amino acids | 1,416 |
|---|---|
| 25,811.2 | |
| 45.47 | |
| 93.28 | |
| −0.053 | |
| 8.18 | |
| 141,880 |
Figure 1Transmembrane structure of GiK.
It contains seven transmembrane segments (S1–S7), the P-loops between S5 and S6 form the pore domain. The selectivity filter is in gray.
Figure 2Domains and motifs related to potassium channels.
GiK presents domains related to different subtypes of potassium channels. (A) Schematic representation. (B) Accession number and description of the sequences.
Prediction of highly conserved residues from GiK.
| Domain or motif | Description | Accession number | Position ( | Server |
|---|---|---|---|---|
| Ion_trans_2 | Ionic channel. This family includes the two membrane helix type ion channels found in bacteria. | 168–245 (1.35e-08) | NCBI Conserved domains, Motif search, InterProScan tool | |
| 227696 | EXS domain-containing protein (Signal transduction mechanisms). | 12–170 (0.44) | ExPASy PROSITE, Motif search | |
| 215625 | Voltage-dependent potassium channel; Provisional. | 181–242 (0.14) | ExPASy PROSITE, Motif search | |
| 236711 | Voltage-gated potassium channel; Provisiona.l | 196–214 (0.70) | ExPASy PROSITE, Motif search | |
| 2POREKCHANEL | Potassium channel domain. | 202–230 (0.00032) | Block searcher | |
| EAGCHANLFMLY | EAG/ELK/ERG potassium channel family signature. | 193–210 (0.029) | Block searcher | |
| KCHANNEL | Potassium channel signature. | 190–212 (0.1) | Block searcher |
Figure 3Multiple sequence alignment of GiK with voltage-gated potassium channels.
The signature sequence T/SXGXGX of the selectivity filter is present in all classes of potassium channels (black square).
Validation scores from RAMPAGE, QMEAN, ProSA-web, ERRAT, and Verify 3D of the constructed models.
| Software | Template (PDB ID) | Ramachandran (%) | QMEAN score | Z-score | ERRAT score | Verify 3D | Residues | RMSD (Å) |
|---|---|---|---|---|---|---|---|---|
| 5TJ6 | 90.4 | 0.141 | −7.56 | 44.26 | 26.28 | 500 | 4.28 | |
| 5U70 | 90.0 | 0.094 | −8.09 | 39.62 | 14.06 | 500 | 5.05 | |
| 5TJI | 94.2 | 0.296 | −5.07 | 69.24 | 35.60 | 500 | 3.90 | |
| 5U76 | 88.4 | 0.023 | −9.22 | 34.97 | 26.28 | 500 | 4.46 | |
| 5TJ6 | 89.8 | 0.191 | −6.92 | 56.64 | 20.60 | 500 | 4.85 | |
| 5TJ6 | 72.9 | 0.101 | −8.78 | 86.58 | 38.80 | 500 | 3.97 | |
| 5U70 | 69.6 | 0.089 | −9.12 | 81.91 | 44.60 | 500 | 5.01 | |
| 5TJ6 | 89.8 | 0.205 | −6.21 | 81.48 | 33.00 | 296 | 0.92 | |
| 5U70 | 92.8 | 0.271 | −5.53 | 87.54 | 39.38 | 292 | 0.91 | |
| 5TJI | 92.5 | 0.240 | −5.82 | 88.57 | 30.98 | 296 | 1.12 | |
| 5U76 | 92.9 | 0.191 | −6.34 | 84.17 | 26.35 | 297 | 1.17 | |
| 5TJ6 | 95.7 | 0.239 | −5.72 | 61.63 | 37.36 | 265 | 1.01 | |
| 5U76 | 94.7 | 0.251 | −5.99 | 35.04 | 38.44 | 372 | 1.10 |
Figure 4Structural validation.
(A) Normalized QMEAN score of theoretical 3D structure for GiK protein model created with SWISS-MODEL server. (B) Graphical representation of the Z-Score of the individual component of QMEAN. (C) ProSA-web Z-scores of all proteins chains in PDB determined by X-ray crystallography (light blue) or NMR spectroscopy (dark blue). The Z score of GiK is highlighted as a black dot. (D) Ramachandran plot analysis, 94.2% of total residues are in the most favored region.
Figure 5Quality estimation of GiK as a membrane protein.
Prediction done with SWISS-MODEL-QMEANBrane tool.
Figure 6Representation of the 3D-GiK modeled structure.
(A) Monomer, (B and C) Tetramer. The images were generated using Maestro software.
Best docking score values (kcal/mol) from the potassium channel blockers to 3D-GiK model.
| Compound | Docking score (kcal/mol) | Compound | Docking score (kcal/mol) | Compound | Docking score (kcal/mol) |
|---|---|---|---|---|---|
| UCL_1684 | −11.2 | ZINC13489790 | −8 | Flecainide | −6.9 |
| ZINC38144725 | −10.8 | Imipramine | −7.9 | Mepivacaine | −6.9 |
| Terfenadine | −10.6 | Trifluoroperazine | −7.9 | ZINC13489786 | −6.8 |
| ZINC00018512 | −10.4 | ZINC13489791 | −7.9 | ZINC13760202 | −6.8 |
| ZINC00598948 | −10.1 | ZINC13489800 | −7.9 | ZINC13777065 | −6.8 |
| Bicuculine | −10 | ZINC13489804 | −7.9 | 1-Ethyl-2-Benzimidazolinone | −6.7 |
| Cromoglicic acid | −10 | ZINC13489830 | −7.9 | ZINC13760207 | −6.7 |
| Penitrem_A | −10 | ZINC13760212 | −7.9 | ZINC13760214 | −6.7 |
| BMS_204352 | −9.4 | Linopirdine | −7.8 | ZINC03935230 | −6.5 |
| NS1643 | −9.1 | ZINC13442157 | −7.8 | ZINC13557606 | −6.5 |
| Paxilline | −9.1 | ZINC13489810 | −7.8 | ZINC13777062 | −6.5 |
| CP_339818 | −9 | ZINC13489818 | −7.8 | ZINC27617403 | −6.5 |
| Tubocurarine | −8.9 | ZINC13489829 | −7.8 | Dofetilide | −6.4 |
| ZINC13489797 | −8.8 | ZINC13489785 | −7.7 | Retigabine | −6.4 |
| UK_78282 | −8.7 | TRAM_34 | −7.6 | ZINC00005768 | −6.4 |
| Verruculogen | −8.7 | ZINC13489794 | −7.6 | ZINC13760203 | −6.4 |
| ZINC13489806 | −8.6 | ZINC13489798 | −7.6 | ZINC13777063 | −6.4 |
| ZINC13644028 | −8.6 | ZINC13489784 | −7.5 | ZINC13777067 | −6.4 |
| DIDS | −8.5 | ZINC13489803 | −7.5 | Correolide | −6.3 |
| ZINC01535217 | −8.5 | ZINC13489813 | −7.5 | ZINC03935234 | −6.3 |
| ZINC13442159 | −8.5 | ZINC13557604 | −7.5 | ZINC03935235 | −6.3 |
| ZINC38144724 | −8.5 | Amitriptyline | −7.4 | ZINC03946466 | −6.3 |
| Bicuculine methiodide | −8.4 | Dequalinium | −7.4 | ZINC13777069 | −6.3 |
| ZINC13489814 | −8.4 | ZINC01539875 | −7.4 | ZINC13777072 | −6.3 |
| ZINC13489817 | −8.4 | ZINC13489789 | −7.4 | Procaine | −6.2 |
| ZINC00015850 | −8.3 | Quinidine | −7.3 | Zoxazolamine | −6.1 |
| ZINC00603820 | −8.3 | ZINC00014006 | −7.3 | ZINC13777058 | −6 |
| ZINC01539867 | −8.2 | ZINC01535218 | −7.3 | ZINC18096411 | −6 |
| ZINC13489795 | −8.2 | ZINC13760206 | −7.3 | ZINC13777075 | −5.8 |
| ZINC13489796 | −8.2 | ZINC27617400 | −7.3 | ZINC13643922 | −5.7 |
| ZINC13489807 | −8.2 | Psora_4 | −7.2 | Chlorzoxazone | −5.5 |
| ZINC13489823 | −8.2 | ZINC18189761 | −7.2 | ZINC13579814 | −5.5 |
| ZINC29309163 | −8.2 | Pimaric_acid | −7.1 | LY_97241 | −5 |
| Niguldipine | −8.1 | Miconazole | −7 | Clofilium | −4.8 |
| ZINC13489799 | −8.1 | ZINC13760204 | −7 | Halothane | −4.5 |
| XE991 | −8 | ZINC13760205 | −7 | 4_Aminopyridine | −4.4 |
| ZINC01539870 | −8 | ZINC13760213 | −7 |
Figure 7GiK—potassium channel blockers docking simulations (A); (B–D) magnified views of the boxed regions depict the three potassium blockers channels binding sites (blue region I, red region II and green region III).
Binding sites from the potassium channel blockers to GiK.
| Region | Amino acid residues | Potassium channel blockers |
|---|---|---|
| Phe218, Val221, Val222, Leu225, Tyr226, Leu250, Leu278, Ile279, Ile456, Arg457, Asp488, Val489, Phe490 | UCL_1684, terfenadine, cromoglicic acid, CP_339818, niguldipine, imipramine, Psora_4, mepivacaine, procaine, chlorzoxazone, 4_Aminopyridine | |
| Leu65, Gly113, Gln116, Leu117, Tyr120, Met122, Phe125, Ile127, Arg129 | Bicuculine, Penitrem_A, BMS_204352, NS1643, paxilline, tubocurarine, UK_78282, DIDS, bicuculine methiodide, trifluoroperazine, amitriptyline, dequalinium, miconazole, flecainide, 1-Ethyl-2-Benzimidazolinone, correolide,clofilium, halothane | |
| Val344, Leu345, Ser346, Val377, Thr379, Gly383, Arg384, Leu388, Leu414, Ala415, Phe418, Pro419 | Verruculogen, XE991, linopirdine, TRAM_34, quinidine, pimaric_acid, dofetilide, retigabine, zoxazolamine, LY_97241 |
Figure 8Ligand interaction diagrams.
UCL 1684 (A), Bicuculline (B) or verruculogen (C). Hydrophobic interactions are depicted by green curves, π–π interactions are in green-dashed lines, and the polar interactions by curve blue lines.